TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages 361-370

  Jain, Meenu ^a   Zhang, Lisa ^a   He, Mei ^a   Zhang, Ya Qin ^b   Shen, Min ^b   Kebebew, Electron ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Aclarubicin; Adrenocortical carcinoma; Invasion; TOP2 inhibitors; TOP2A

Indexed keywords

ACLARUBICIN; AMSACRINE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GATIFLOXACIN; IDARUBICIN; IRINOTECAN; MESSENGER RNA; MITOTANE; MITOXANTRONE; NORDIFLOXACIN; PIRARUBICIN; RUBITECAN; TENIPOSIDE; TOPOISOMERASE ALPHA 2; TOPOTECAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; PROTEIN EXPRESSION; TUMOR SPHEROID;

ACLARUBICIN; ADRENOCORTICAL CARCINOMA; INVASION; TOP2 INHIBITORS; TOP2A;

ACLARUBICIN; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; GENE KNOCKDOWN TECHNIQUES; HUMANS; RNA, MESSENGER; RNA, SMALL INTERFERING; TOPOISOMERASE II INHIBITORS;

EID: 84879478419     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0403     Document Type: Article

References (45)

1. Allolio B & Fassnacht M 2006 Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 91 2027-2037. (doi:10.1210/jc.2005-2639)
2. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D et al. 2012 The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 603-607. (doi:10.1038/nature11003)
3. Bedard PL, Dinh P, Sotiriou C & Piccart-Gebhart MJ 2009 Aiming at the target: improved adjuvant medical therapy. Breast 18 (Suppl 3) S25-S30. (doi:10.1016/S0960-9776(09)70268-1)
4. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F et al. 2005 Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocrine-Related Cancer 12 657-666. (doi:10.1677/erc.1.01025)
5. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E & Sturgeon C 2008 Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113 3130-3136. (doi:10.1002/cncr. 23886)
6. Coss A, Tosetto M, Fox EJ, Sapetto-Rebow B, Gorman S, Kennedy BN, Lloyd AT, Hyland JM, O'Donoghue DP, Sheahan K et al. 2009 Increased topoisomerase IIα expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis. Cancer Letters 276 228-238. (doi:10.1016/j.canlet.2008.11.018)
7. Dawany NB, Dampier WN & Tozeren A 2011 Large-scale integration of microarray data reveals genes and pathways common to multiple cancer types. International Journal of Cancer 128 2881-2891. (doi:10.1002/ijc.25854)
8. Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B et al. 2011 Multifactorial approach to predicting resistance to anthracyclines. Journal of Clinical Oncology 29 1578-1586. (doi:10.1200/JCO.2010.31.2231)
9. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B et al. 2012 Combination chemotherapy in advanced adrenocortical carcinoma. New England Journal of Medicine 366 2189-2197. (doi:10.1056/NEJMoa1200966)
10. Favia G, Lumachi F, Carraro P & D'Amico DF 1995 Adrenocortical carcinoma. Our experience. Minerva Endocrinologica 20 95-99.
11. Fernandez-Ranvier GG, Weng J, Yeh RF, Khanafshar E, Suh I, Barker C, Duh QY, Clark OH & Kebebew E 2008 Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Archives of Surgery 143 841-846 (discussion 846). (doi:10.1001/archsurg.143.9.841)
12. Fornari FA, Jr, Jarvis DW, Grant S, Orr MS, Randolph JK, White FK & Gewirtz DA 1996 Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochemical Pharmacology 51 931-940. (doi:10.1016/0006-2952(96)00050-0)
13. Gieseler F, Bauer E, Nuessler V, Clark M & Valsamas S 1999 Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage. Leukemia 13 1859-1863. (doi:10.1038/sj.leu.2401570)
14. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW et al. 2003 Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. American Journal of Pathology 162 521-531. (doi:10.1016/S0002-9440(10)63846-1)
15. Gobble RM, Qin LX, Brill ER, Angeles CV, Ugras S, O'Connor RB, Moraco NH, Decarolis PL, Antonescu C & Singer S 2011 Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Research 71 2697-2705. (doi:10.1158/0008-5472.CAN-10-3588)
16. Han JW, Dionne CA, Kedersha NL & Goldmacher VS 1997 p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc. Cancer Research 57 176-182.
17. Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB et al. 1991 Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark. Leukemia 5 510-516.
18. Icard P, Louvel A, Le Charpentier M & Chapuis Y 2001 Adrenocortical tumors with oncocytic cells: benign or malignant? Annales de Chirurgie 126 249-253. (doi:10.1016/S0003-3944(01)00497-7)
19. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, Zheng W & Austin CP 2006 Quantitative high-throughput screening: a titrationbased approach that efficiently identifies biological activities in large chemical libraries. PNAS 103 11473-11478. (doi:10.1073/pnas.0604348103)
20. Jain M, Zhang L, He M, Patterson EE, Nilubol N, Fojo AT, Joshi B, Puri R & Kebebew E 2012 Interleukin-13 receptor α2 is a novel therapeutic target for human adrenocortical carcinoma. Cancer 118 5698-5708. (doi:10.1002/cncr.27629)
21. Jeannesson P, Lahlil R, Chenais B, Devy L, Gillet R, Aries A, Morceau F & Trentesaux C 1997 Anthracyclines as tumor cell differentiating agents: effects on the regulation of erythroid gene expression. Leukemia & Lymphoma 26 575-587.
22. Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY, Huang J, Mao LP, Tong Y, Wang L et al. 2006 Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 20 1361-1367. (doi:10.1038/sj.leu.2404287)
23. Karanes C, Young JD, Samson MK, Smith LB, Franco LA & Baker LH 1983 Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study. Investigational New Drugs 1 173-179. (doi:10.1007/BF00172077)
24. Kebebew E, Reiff E, Duh QY, Clark OH & McMillan A 2006 Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World Journal of Surgery 30 872-878. (doi:10.1007/s00268-005-0329-x)
25. Kern W, Braess J, Grote-Metke A, Kuse H, Fuchs R, Hossfeld DK, Reichle A, Wormann B, Buchner T & Hiddemann W 1998 Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. German AML Cooperative Group. Leukemia 12 1522-1526. (doi:10.1038/sj.leu.2401155)
26. Kosari F, Munz JM, Savci-Heijink CD, Spiro C, Klee EW, Kube DM, Tillmans L, Slezak J, Karnes RJ, Cheville JC et al. 2008 Identification of prognostic biomarkers for prostate cancer. Clinical Cancer Research 14 1734-1743. (doi:10.1158/1078-0432.CCR-07-1494)
27. Lombardi CP, Raffaelli M, Pani G, Maffione A, Princi P, Traini E, Galeotti T, Rossi ED, Fadda G & Bellantone R 2006 Gene expression profiling of adrenal cortical tumors by cDNA macroarray analysis. Results of a preliminary study. Biomedicine & Pharmacotherapy 60 186-190. (doi:10.1016/j.biopha. 2006.03.006)
28. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P et al. 1990 Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New England Journal of Medicine 322 1195-1201. (doi:10.1056/ NEJM199004263221705)
29. Malhotra S, Lapointe J, Salari K, Higgins JP, Ferrari M, Montgomery K, van de Rijn M, Brooks JD & Pollack JR 2011 A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer. PLoS ONE 6 e20293. (doi:10.1371/journal.pone.0020293)
30. Morceau F, Aries A, Lahlil R, Devy L, Jardillier JC, Jeannesson P & Trentesaux C 1996 Evidence for distinct regulation processes in the aclacinomycin- and doxorubicin-mediated differentiation of human erythroleukemic cells. Biochemical Pharmacology 51 839-845. (doi:10.1016/0006-2952(95)02240-6)
31. Nitiss JL 2009 Targeting DNA topoisomerase II in cancer chemotherapy. Nature Reviews. Cancer 9 338-350. (doi:10.1038/nrc2607)
32. Schaefer A, Dahle M, Radenz G, Steinheider G & Marquardt H 1991 Structure-activity relationship between anthracycline-induced differentiation and inhibition of glycoprotein synthesis in Friend erythroleukemia cells. Leukemia 5 95-100.
33. Schutte J, Niederle N & Seeber S 1983 Phase II trial of aclacinomycin A in acute leukemia and various solid tumors. Journal of Cancer Research and Clinical Oncology 105 162-165. (doi:10.1007/BF00406927)
34. Slater EP, Diehl SM, Langer P, Samans B, Ramaswamy A, Zielke A & Bartsch DK 2006 Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. European Journal of Endocrinology 154 587-598. (doi:10.1530/eje.1.02116)
35. Song YP, Tong Y, Qian WB, Mai WY, Meng HT, Qian JJ, Tong HY, Huang J, Mao LP, Xu WL et al. 2011 The efficacy and safety of HAA regimen as induction chemotherapy in 150 newly diagnosed acute myeloid leukemia. Zhonghua Nei Ke Za Zhi 50 48-51.
36. Sorensen BS, Sinding J, Andersen AH, Alsner J, Jensen PB & Westergaard O 1992 Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. Journal of Molecular Biology 228 778-786. (doi:10.1016/0022-2836(92) 90863-F)
37. Suzushima H, Wada N, Yamasaki H, Eto K, Shimomura T, Kugimiya MH, Horikawa K, Nishimura S, Tsuda H, Mitsuya H et al. 2009 Low-dose cytarabine and aclarubicin in combination with granulocyte colonystimulating factor for elderly patients with previously untreated acute myeloid leukemia. Leukemia Research 34 610-614. (doi:10.1016/j.leukres.2009.08.010)
38. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E et al. 2007a Adjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine 356 2372-2380. (doi:10.1056/NEJMoa063360)
39. Terzolo M, Reimondo G, Bovio S, Daffara F, Allasino B, Minetto M & Angeli A 2007b Management of adrenal incidentalomas. Experimental and Clinical Endocrinology & Diabetes 115 166-170. (doi:10.1055/s-2007-970408)
40. Tretiakova M, Turkyilmaz M, Grushko T, Kocherginsky M, Rubin C, Teh B & Yang XJ 2006 Topoisomerase IIα in Wilms' tumour: gene alterations and immunoexpression. Journal of Clinical Pathology 59 1272-1277. (doi:10.1136/jcp.2005.031963)
41. Velazquez-Fernandez D, Laurell C, Geli J, Hoog A, Odeberg J, Kjellman M, Lundeberg J, Hamberger B, Nilsson P & Backdahl M 2005 Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 138 1087-1094. (doi:10.1016/j.surg. 2005.09.031)
42. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, Zerbini MC, Liberman B, Carlos Gomes G & Kirschner MA 2000 Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88 711-736. (doi:10.1002/(SICI)1097-0142(20000215)88:4!711::AID-CNCR1O3.0.CO;2-W)
43. Wang Y, Li W, Chen S, Qiu H, Sun A & Wu D 2011 Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21). Leukemia Research 35 604-607. (doi:10.1016/j.leukres.2010.11.003)
44. Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, Koh J, Chan SL, Chan AT, Lai PB et al. 2009 TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. International Journal of Cancer 124 644-652. (doi:10.1002/ijc.23968)
45. Yamada K, Nakamura T, Tsuruo T, Kitahara T, Maekawa T, Uzaka Y, Kurita S, Masaoka T, Takaku F, Hirota Y et al. 1980 A phase II study of aclacinomycin A in acute leukemia in adults. Cancer Treatment Reviews 7 177-182. (doi:10.1016/S0305-7372(80)80033-8)